Results 21 to 30 of about 1,993 (117)

Post-PRRT scans: which scans to make and what to look for

Cancer Imaging, 2022
Aim The aim of this study was to evaluate the clinical utility of SPECT/CT (imaging of uptake in tumor lesions and additional findings) and the additional value of planar imaging in order to simplify clinical imaging protocols and decrease patients ...
Else A. Aalbersberg, Daphne M. V. de Vries–Huizing, Margot E. T. Tesselaar, Marcel P. M. Stokkel, Michelle W. J. Versleijen   +4 more
doaj   +1 more source

Literature overview of subacute CTCAE haematotoxicity during PRRT (% of patients).

, 2021
Literature overview of subacute CTCAE haematotoxicity during PRRT (% of patients).
Daphne M. V. de Vries–Huizing (11725367), Iris Walraven (9227974), Martine M. Geluk–Jonker (11725373), Berlinda J. de Wit–van der Veen (11725379), Michelle W. J. Versleijen (9227968), Michiel Sinaasappel (11725370), Marcel P. M. Stokkel (9227983), Margot E. T. Tesselaar (9227971), Jeroen J. M. A. Hendrikx (11725376)   +8 more
core   +1 more source

Combination of [¹⁷⁷Lu]Lu-DOTA-TATE Targeted Radionuclide Therapy and Photothermal Therapy as a Promising Approach for Cancer Treatment: In Vivo Studies in a Human Xenograft Mouse Model

Pharmaceutics, 2022
Peptide receptor radionuclide therapy (PRRT) relies on α- and β-emitting radionuclides bound to a peptide that commonly targets somatostatin receptors (SSTRs) for the localized killing of tumors through ionizing radiation.
Marina Simón, Jesper Tranekjær Jørgensen, Harshvardhan A. Khare, Camilla Christensen, Carsten Haagen Nielsen, Andreas Kjaer   +5 more
doaj   +1 more source

Peptide receptor radionuclide therapy of neuroendocrine tumors: Case series [PDF]

Archive of Oncology, 2012
Background: Peptide Receptor Radionuclide Therapy (PRRT) is novel and efficacious treatment of neuroendocrine tumors (NETs). Methods: Twenty-seven patients (14 females, 13 males, mean age 54.37±11.14 years; range 30-74 years) with progressive ...
Matović Milovan
doaj   +1 more source

Long-Term Survival and Value of ¹⁸F-FDG PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with Second Peptide Receptor Radionuclide Therapy Course with ¹⁷⁷Lu-DOTATATE

Life, 2021
Peptide receptor radionuclide therapy (PRRT) has been recognized as a promising therapy against neuroendocrine tumors (NETs). The use of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) in NETs has been a matter of controversy.
Margarida Rodrigues, Kevin-Klaus Winkler, Hanna Svirydenka, Bernhard Nilica, Christian Uprimny, Irene Virgolini   +5 more
doaj   +1 more source

Response to targeted radionuclide therapy with [131I]MIBG AND [177Lu]Lu-DOTA-TATE according to adrenal vs. extra-adrenal primary location in metastatic paragangliomas and pheochromocytomas: A systematic review

Frontiers in Endocrinology, 2022
PurposeTargeted radionuclide therapy (TRT) with [131I]MIBG and [177Lu]Lu-DOTA-TATE is an alternative treatment to the classic schemes in slow progressive metastatic/inoperable paraganglioma (PGL) and pheochromocytoma (PHEO).
Stefan Prado-Wohlwend, María Isabel del Olmo-García, Pilar Bello-Arques, Juan Francisco Merino-Torres, Juan Francisco Merino-Torres   +4 more
doaj   +1 more source

Neoadjuvant PRRT for advanced pNEN: an unusual highlander

, 2021
A case of pancreatic neuroendocrine neoplasm treated with neoadjuvant PRRT before sugery, obtaining complete tumor ...
Ambrosio, Maria Rosaria, Zatelli, Maria Chiara, Zanata, Isabella   +2 more
core   +1 more source

Induction of Anti-Tumor Immune Responses by Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in a Murine Model of a Human Neuroendocrine Tumor

Diagnostics, 2013
Peptide receptor radionuclide therapy (PRRT) is a relatively new mode of internally targeted radiotherapy currently in clinical trials. In PRRT, ionizing radioisotopes conjugated to somatostatin analogues are targeted to neuroendocrine tumors (NETs) via ...
Michael Bzorek, Michael Holmsgaard Kristensen, Andreas Kjaer, Andreas Klaus Pfeifer, Ulrich Knigge, Yin Wu, Rajendra Singh Garbyal, Palle Rasmussen, Rebecca Myschetzky   +8 more
doaj   +1 more source

Image_1_New Insights in PRRT: Lessons From 2021.tif

, 2022
Peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin analogs has been used for over two decades for the treatment of well-differentiated neuroendocrine tumors (NETs), and the publication of the NETTER-1 trials has further ...
Giulia Puliani (10692075), Marilda Mormando (12344704), Rosa Lauretta (12344707), Marialuisa Appetecchia (7539743), Marta Bianchini (715381), Alfonsina Chiefari (12344701)   +5 more
core   +1 more source

Histopathological and Immunophenotypic Changes of Pancreatic Neuroendocrine Tumors after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT)

, 2020
Peptide Receptor Radionuclide Therapy (PRRT) is an emerging therapeutic option for pancreatic neuroendocrine tumors (PanNETs). A possible role for PRRT as a neoadjuvant agent is still largely undetermined, explored only in case reports or small case ...
Bertani, Emilio, Schiavo Lena, Marco, Bartolomei, Mirco, Pisa, Eleonora, Partelli, Stefano, Doglioni, Claudio, Falconi, Massimo, Andreasi, Valentina, Zamboni, Giuseppe, Castelli, Paola, Smart, Chanel Elisha   +10 more
core   +1 more source